CRANBURY, N.J.--(BUSINESS WIRE)--Rare Disease Report® (RDR®) and CURE® magazine have joined forces with the Fibrolamellar Cancer Foundation (FCF) through the Strategic Alliance Partnership (SAP) program, announced Michael J. Hennessy Jr., president of Michael J. Hennessy Associates, parent company of RDR® and CURE® magazine.
In making the announcement, Michael J. Hennessy Jr said, “We are thrilled to raise awareness for this rare type of liver cancer. FCF has been a pioneer in assisting patients affected by fibrolamellar hepatocellular carcinoma and exemplifies the fundamental principle that CURE® magazine was founded on: to assist patients as they navigate through their cancer journey. With this partnership, we aim to raise awareness and funds to enhance care for those affected by this rare disease.”
Fibrolamellar hepatocellular carcinoma (FHC) is an atypical liver cancer that impacts adolescents and young adults with no history of liver disease. As it only impacts 1 in 5 million individuals, it is considered ultra rare. Symptoms include abdominal, shoulder, or back pain; loss of appetite; weight loss; jaundice; and a palpable mass. Standard treatment includes surgical removal of the tumor or nonsurgical therapy.
“Strengthening awareness and fostering collaboration for ultra rare cancers such as fibrolamellar, is a critical part our the FCF’s mission,” states John Hopper, FCF President. “ The Strategic Alliance Partnership with Michael J. Hennessy Associates is ideal in meeting this goal today and in the future, for both healthcare professionals and the patient community.”
FCF is a charitable organization that channels 100% of its net donations to scientific research, striving to help spread awareness and support patients and their families. The organization was founded by Tucker Davis and his friends Alisha Sternenberger, Charles Beermann and Derek Gilchrist, in 2009 after Tucker was diagnosed with the disease. Little research was being conducted at the time on FHC, so the foundation’s mission was, and continues to be, three-fold:
- Find a cure and treatment options
- Raise awareness of FHC
- Connect and support the fibrolamellar community of patients and their families
For more information on FCF, please visit www.raredr.com/sap-partner and www.curetoday.com/advocacy.
About CURE Media Group
CURE Media Group is a leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, N.J.-based Michael J. Hennessy Associates, Inc., family of businesses, which includes the acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com.
About Rare Disease Communications®
Rare Disease Communications® is a health care communications and media company focused on the rare disease community and dedicated to raising awareness of rare diseases and orphan drugs so that patients will be diagnosed and treated more efficiently. Rare Disease Communications® is part of the Michael J. Hennessy Associates, Inc. family of businesses, based in Cranbury, N.J. MJH Associates is dedicated to improving quality of life through health care education, research and communication. To learn more, visit http://www.mjhassoc.com.
